Background: As new drugs are introduced onto the market, it is important to determine those that can cause cutaneous reactions and with what frequency. In addition, drugs that have been used for a long period of time may cause new types of eruption that have not been observed previously. The purpose of this study was to evaluate the types of drug eruption and the causative agents in a hospital-based population for a period of 1 year.
Methods: All in- and outpatients consulting for drug eruptions at the Dermatology Clinic, Ramathibodi Hospital from June 1995 to May 1996 were included in the study. The history and physical examination were performed by one of the authors. In suspected cases, a skin biopsy was carried out to confirm the diagnosis. Rechallenge tests with suspected drugs were performed with informed consent.
Results: One hundred and thirty-two patients were enrolled in the study. The most common types of drug eruption were maculopapular eruption, fixed drug eruption, and urticaria. Antimicrobial agents were found to be the most common causative drugs, followed by antipyretic/anti-inflammatory agents and drugs acting on the central nervous system.
Conclusions: Although the most common type of drug eruption and the most common causative agents were not different from those found in previous studies, the new generation of antibiotics and antifungal agents were found to be a frequent cause of drug eruptions. New types of drug eruption, such as generalized exanthematous pustulosis and acral erythema, were observed in this study.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1046/j.1365-4362.1998.00378.x | DOI Listing |
Acta Endocrinol (Buchar)
January 2025
Municipal Clinical Hospital - Urology, Cluj-Napoca.
Background: Sweet's syndrome (SS) or acute febrile neutrophilic dermatosis is a dermatological illness that can be described by tender erythematous plaques or nodules and acute onset fever. The etiology is multifactorial and is not fully understood. SS is separated in three subclasses: classical, malignancy-associated, and drug-induced.
View Article and Find Full Text PDFJAAD Case Rep
February 2025
Department of Dermatology, Temple University Lewis Katz School of Medicine, Philadelphia, Pennsylvania.
Front Neurol
January 2025
Department of Neurosurgery, Nakamura Memorial Hospital, Sapporo, Japan.
Background: There is no established treatment for the acute exacerbation of trigeminal neuralgia. We aimed to investigate the efficacy and safety of intravenous fosphenytoin for this disease.
Methods: We conducted a retrospective observational study of data from 41 patients with trigeminal neuralgia who received intravenous fosphenytoin therapy.
Med Mycol Case Rep
March 2025
Department of Dermatology, Tenri Hospital, 200 Mishima, Tenri, Nara, 632-8552, Japan.
We report a case of kerion celsi caused by in a teenage male judo athlete, presenting with a lesion in the occipital region. Following the initiation of systemic antifungal therapy, the patient developed a dermatophytid reaction, necessitating differentiation from a drug eruption. Direct microscopy of the affected area confirmed the presence of fungal elements, and histopathological examination revealed endothrix invasion, supporting the continuation of treatment.
View Article and Find Full Text PDFJ Dermatol
January 2025
Department of Dermatology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!